CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 204 enrolled
Drug / intervention
Vedolizumab SCdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03961308
NCT03961308Phase 1Completed

A Phase 1, Open-Label, Randomized, Parallel Group Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of Vedolizumab Administered in Prefilled Syringe Versus Prefilled Syringe in Autoinjector in Healthy Subjects

Takeda·interventional·Posted May 23, 2019·Updated Nov 14, 2019

In Brief

A Phase 1 clinical trial evaluating Vedolizumab SC for Healthy Volunteers. Completed, enrolled 204 participants across 2 sites.

Detailed Summary

The purpose of this study is to compare the PK of single dose of Vedolizumab SC 108 milligram (mg) administered as PFS vs investigational device.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedMay 23, 2019
Enrollment StartMar 12, 2018
Primary CompletionOct 20, 2018
Study CompletionNov 21, 2018
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.1 years ago

Interventions

Vedolizumab SCdrug

Vedolizumab SC liquid.